Author(s)
Nuria Perulero, Bsc, Psychologist1, Felipe Cardenal, MD, Physician2, Ramón Garcia, MD, Physician3, Oscar Juan, MD, Physician4, Sergio Vázquez, MD, Physician5, Isidoro Barneto, MD, Physician6, Cristina Varela, Bsc, Pharmacoeconomic Specialist71IMS Health, Barcelona, Spain; 2 ICO. Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; 3 Hospital General Universitario Gregorio Marañón, Madrid, Spain; 4 Hospital Arnau de Vilanova, Valencia, Spain; 5 Complexo Hospitalario Xeral Calde, Lugo, Spain; 6 Hospital General Universitario Reina Sofía, Córdoba, Spain; 7 Roche Farma, Madrid, Spain
OBJECTIVES: To know which attributes related to treatment administration are valued highly in patients with lung cancer through the conjoint analysis. METHODS: A literature review was carried out to identify the attributes related to treatment. There were 6 attributes:1-Time spent in the hospital for treatment administration. 2-Immediate toxicity. 3- Symptoms' control. 4- Confidence with the physician. 5- Survival. 6-Treatment administration. Taking into account these attributes we elaborated 16 hypothetic scenarios. Through interviews with 2nd line lung cancer patients we asked them to order by preferred scenario. RESULTS: 24 patients were interviewed, with a mean (SD) age of 60.8 (11.6) years. 58.3% were men. The mean range by priority order, that is to say, of priority 1 (maximum preference) to priority 16 (minimum preference), we observed that the chosen scenarios in the first place were N (No time spent in the hospital/No immediate toxicity/Moderate symptom control/Quite a lot of confidence with the physician/More than 6 months survival/Oral administration) and H (Spending 2 hours per day during one week in the hospital/No immediate toxicity/Total control of symptoms/Total confidence with the physician/Less than 3 months of survival/Oral administration), whereas the ones less preferred were M (Spending 2 hours per day during one week in the hospital/No immediate toxicity/No symptom control/Any confidence with the physician/From 3-6 month survival/Intravenous administration) and J (No time spent in the hospital/High immediate toxicity/No symptom control/Any confidence with the physician/Less than 6 months of survival/Intravenous administration). The factors that influence more on the treatment preferences were, symptoms' control (31% of the patients), confidence with the physician (21.6%) and immediate toxicity (18.7%). CONCLUSION: Through a conjoint analysis we may conclude that the most important attributes for the patients were symptoms' control followed by confidence with their physician.
Conference/Value in Health Info
2007-10, ISPOR Europe 2007, Dublin, Ireland
Value in Health, Vol. 10, No. 6 (November/December 2007)
Code
PCN71
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Oncology